Linked Life Data

11794358

Source:http://linkedlifedata.com/resource/pubmed/id/11794358

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2002-1-15
pubmed:abstractText
In 1991 a most-favored customer (MFC) rule was adopted to govern pharmaceutical prices paid by Medicaid. Theoretical models show that an MFC rule commits a firm to compete less aggressively in prices. I find that the price of branded products facing generic competition rose (4% on average). Brands protected by patents did not significantly increase in price. Generics in concentrated markets should display a strategic response to the brand's adoption of the MFC; I find that generic firms raise price more as their markets become concentrated. Hospital prices show little change. The results suggest that the MFC rule caused higher prices for some pharmaceutical customers.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
T
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0741-6261
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
HSR
pubmed:authorsComplete
Y
pubmed:pagination
269-90
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules.
pubmed:affiliation
Stanford University, USA. fionasm@crown.stanford.edu
pubmed:publicationType
Journal Article